Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

Blood

Volumn 107, Issue 4, 2006, Pages 1292-1298

  Facon, Thierry ^a   Mary, Jean Yves ^b   Pégourie, Brigitte ^b   Attal, Michel ^b   Renaud, Marc ^b   Sadoun, Alain ^b   Voillat, Laurent ^b   Dorvaux, Véronique ^b   Hulin, Cyrille ^b   Lepeu, Gérard ^b   Harousseau, Jean Luc ^b   Eschard, Jean Paul ^b   Ferrant, Augustin ^b   Blanc, Michel ^b   Maloisel, Frédéric ^b   Orfeuvre, Hubert ^b   Rossi, Jean Franc̃ois ^b   Azaïs, Isabelle ^b   Monconduit, Mathieu ^b   Collet, Philippe ^b   Anglaret, Bruno ^b   Yakoub Agha, Ibrahim ^b   Wetterwald, Marc ^b   Eghbali, Houchingue ^b   Vekemans, Marie Christine ^b   Maisonneuve, Hervé ^b   Troncy, Jacques ^b   Grosbois, Bernard ^b   Doyen, Chantal ^b   Thyss, Antoine ^b   Jaubert, Jérome ^b   Casassus, Philippe ^b   Thielemans, Béatrice ^b   Bataille, Régis ^b   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; DEXAMETHASONE; MELPHALAN; PREDNISONE;

AGED; AMYLOIDOSIS; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; INFECTION; LEUKEMIA; LIVER TOXICITY; LUNG DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; MULTIPLE MYELOMA; NEUROTOXICITY; PATIENT; PERFORATED DIVERTICULUM; PRIORITY JOURNAL; PSYCHIATRY; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEPTICEMIA; SIDE EFFECT; SURVIVAL;

EID: 32644438680     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1588     Document Type: Article

References (17)

1. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208:1680-1685.
2. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
3. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986;105:8-11.
4. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80:887-890.
5. Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol. 2004;127:159-164.
6. Dimopoulos MA, Weber D, Delasalle KB, Alexanian R. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. Cancer. 1993;72:2589-2592.
7. Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol. 1994;12:2405-2414.
8. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
9. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Cox D. Regression models and life-tables (with discussions). J Roy Stat Soc B. 1972;34:184-192.
11. Cox D, Oakes D. Analysis of Survival Data. London, England: Chapman & Hall; 1984.
12. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
13. Byar D. Identification of prognostic factors. In: Buyse ME, Staquet MJ, Sylvester RJ, eds. Cancer Clinical Trials: Methods and Practice. Oxford, England: Oxford Medical Publications; 1988:423-443.
14. Facon T, Mary JY, Attal M, et al. Melphalan-prednisone versus dexamethasone-based regimens for newly diagnosed myeloma patients aged 65-75 years. Presented at: VII International Multiple Workshop; September 1999; Stockholm, Sweden.
15. Andersen PK. Conditional power calculations as an aid in the decision whether to continue a clinical trial. Control Clin Trials. 1987;8:67-74.
16. Rajkumar SV, Blood E, Vesole D, Shepard R, Greipp PR. Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a phase III trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood. 2004;104:63a. Abstract 205.
17. Barlogie B, Kyle R, Anderson K, et al Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/mm2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroupe trial S9321 [abstract]. Blood. 2003;102:42a.